Section 5—Corporate Governance and Management
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 13, 2018, the Board of Directors (the “Board”) of Mattel, Inc. (“Mattel” or the “Company”) elected Dr. Judy Olian as a new director of Mattel and approved an increase in the size of the Board from nine to ten directors, in each case effective immediately. In accordance with Mattel’s director compensation program, Dr. Olian will be entitled to a cash retainer of $75,000 and a grant of restricted stock units valued at $105,000 (based on the closing price of Mattel’s common stock on the grant date of September 13, 2018), which represents apro-ration of the annual director compensation based on the number of months (including partial months) she will serve from September 2018 to the date of Mattel’s 2019 Annual Meeting of Stockholders.
Dr. Olian, 66, has served as the ninth President of Quinnipiac University since July 2018. She previously served as the Dean and John E. Anderson Chair in Management at UCLA Anderson School of Management from January 2006 to July 2018. Dr. Olian currently serves as a director and member of the audit committee of Ares Management LLC, a global alternative asset manager. She also serves as a director and member of the compensation committee of United Therapeutics Corp., a biotechnology company addressing the needs of patients with chronic and life-threatening conditions. In addition, she is a member of the advisory board of Catalyst Inc., a global nonprofit organization that engages in research and advocacy to accelerate the progress of women in the workplace.
Dr. Olian has not been named to a committee of the Board of Directors at this time.
There are no transactions between Dr. Olian and Mattel that would be reportable under Item 404(a) of RegulationS-K.
Section 7 – Regulation FD
Item 7.01. Regulation FD Disclosure.
On September 13, 2018, Mattel issued a press release regarding the election of Dr. Olian, a copy of which is furnished as Exhibit 99.1 hereto.
In accordance with General Instruction B.2 of Form8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
** Furnished herewith
